A5083135815- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Psoriasis: Treatment and Pathogenesis
- Dermatology and Skin Diseases
- Mast cells and histamine
- Monoclonal and Polyclonal Antibodies Research
University of Lübeck
2017-2024
IL-17A has been identified as key regulatory molecule in several autoimmune and chronic inflammatory diseases followed by the successful use of anti-IL-17 therapy, e.g. ankylosing spondylitis psoriasis. Bullous pemphigoid (BP) is most frequent blistering disease with a high need for more specific, effective safe treatment options. The aim this study was to clarify pathophysiological importance BP. We found elevated numbers IL-17A+ CD4+ lymphocytes peripheral blood BP patients CD3+ cells...
A balanced immune system is essential to maintain adequate host defense and effective self-tolerance. While an that fails generate appropriate response will permit infections develop, uncontrolled activation may lead autoinflammatory or autoimmune diseases. To identify drug candidates capable of modulating cell functions, we screened 1200 small molecules from the Prestwick Chemical Library for their property inhibit innate adaptive responses. Our studies focused specifically on interactions...
Mucous membrane pemphigoid (MMP) is an autoimmune blistering disease characterized by autoantibodies against the basal zone of skin and surface-close epithelia predominant mucosal lesions. The oral cavity conjunctivae are most frequently affected, albeit clinical manifestations can also occur on skin. MMP-associated lesions outside typically lead to scarring. Mechanisms underlying scarring largely unknown in MMP effective treatment options limited. Herein, we assessed collagen architecture...